RxDoctor Payments Data

Peter Varunok, MD

Gastroenterology · Poughkeepsie, NYNPI 1598769283

Payments from drug & device makers

$53,804in general payments, 2019–2025

Across 180 payments — averaging $298.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$27K
  • Gilead$14K
  • Intercept Pharmaceuticals, Inc.$12K
  • Romark Laboratories, LC$320
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$242
  • QOL Medical, LLC$182
  • plus $1K from 21 others

What the payments were for

  • Speaking & faculty fees$11,69068%
  • Travel & lodging$1,3678%
  • Food & beverage$4,13624%
  • Education$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,804 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$165,317
Medicare patients
365
Services billed
4,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid13$124,937
XifaxanRifaximin36$124,151
LinzessLinaclotide78$68,827
CreonLipase/Protease/Amylase15$52,886
RezdiffraResmetirom11$41,914
SutabSod Sulf/Pot Chloride/Mag Sulf91$14,579
Ursodiol34$9,194
Dexlansoprazole DrDexlansoprazole15$6,733
Mesalamine16$5,600
Budesonide EcBudesonide15$4,311
Sucralfate59$3,578
Omeprazole250$3,159
Famotidine204$2,995
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates35$1,964
Lansoprazole23$1,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$11,862$124,93713 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$242$124,15136 claims
AbbVieLinzess, Creon, Delzicol$26,520$122,304104 claims
Madrigal PharmaceuticalsRezdiffra$34$41,91411 claims
Braintree Laboratories, Inc.Sutab$49$14,57991 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →